首頁 > 市場調查報告書 > 製藥

生物製劑

Bcr Abl蛋白酪氨酸激梅抑制劑的全球市場:藥價，銷售額，臨床試驗趨勢(2029年)

市場調查報告書

商品編碼

1298475

Bcr Abl蛋白酪氨酸激梅抑制劑的全球市場:藥價，銷售額，臨床試驗趨勢(2029年)

Global Bcr Abl Tyrosine Kinase Inhibitor Drug Market, Drug Price, Sales and Clinical Trials Insight 2029

出版日期: 2023年06月01日 | 出版商:

KuicK Research | 英文 240 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球Bcr Abl蛋白酪氨酸激梅抑制劑的市場機會價值80億美元。

本報告提供全球Bcr Abl蛋白酪氨酸激梅抑制劑市場相關調查，提供市場概要，以及藥物趨勢，臨床試驗趨勢，各地區趨勢，及加入此市場的主要企業的競爭情形等資訊。

1St Biotherapeutics
Aerovate Therapeutics
Ascentage Pharma
AtlasMedx
Bayer HealthCare
BenevolentAI
CSPC Ouyi Pharmaceutical
Deciphera Pharmaceuticals
Exvastat
Fusion Pharma
Georgetown University
Guangzhou Institutes of Biomedicine and Health
Il-Yang
Inhibikase Therapeutics
Jiangsu Hansoh Pharmaceutical
Novartis
Novartis Pharmaceuticals Corporation
Pfizer
Pharm-Sintez
Shenzhen TargetRx
Sun Pharma Advanced Research Company
Takeda
Terns Pharmaceuticals
Theseus Pharmaceuticals
Vectura
Xspray Pharma
YD Global Life Science

簡介目錄圖表

“Global Bcr Abl Tyrosine Kinase Inhibitor Drug Market, Drug Price, Sales & Clinical Trials Insight 2029” Report Highlights:

Global Bcr Abl Inhibitor Drug Market Opportunity: > USD 8 Billion
Bcr Abl Inhibitor Drug Market Global & Regional Analysis
Approved Drugs Sales Insight (2019 - Q1'2023)
Approved Drugs Dosage, Patent & Price Insight
Bcr Abl Inhibitors Drugs Clinical Trials By Company, Indication & Phase: > 20 Drugs
Clinical Insight On Approved Bcr Abl Inhibitors Drugs: 10 Drugs
Competitive Landscape: Insight on 27 Companies

Bcr Abl inhibitors have transformed the treatment landscape for patients of chronic myeloid leukemia (CML). These inhibitors work by blocking the activity of the constitutively active Bcr Abl fusion protein, which is encoded by the unnatural BCR-ABL gene, itself a product of chromosomal translocation. By directly acting on the protein held responsible for the development of this form of leukemia, researchers and drug developers have achieved great success in the past few years and so have these patients, who were mainly treating through chemotherapy, an approach coming with several adverse effects. At present, there are seven BCR-ABL inhibitors that have been approved for commercialization across the world along with some more that have approvals in specific regions. The market for BCR-ABL inhibitors is driven by the increasing cases of myeloid leukemia, and is expected to see high growth in the coming years.

Imatinib was the first Bcr Abl inhibitor to be approved for the treatment of chronic myeloid leukemia, and as a first-generation inhibitor, its clinical and commercial success led to the development of more efficient Bcr Abl inhibitors. It was commercialized across the world by the names of Gleevec and Glivec. However, following the expiration of its patent, Gleevec and Glivec have faced severe competition from generic versions of Imatinib, which have been challenging their share in the global market and have managed to chip off its sales. However, with the presence other Bcr Abl inhibitors in the market and more in the pipelines, sales of Bcr Abl inhibitors are expected to dominate over generic drugs' sales.

Scemblix (Asciminib) was the most recent Bcr Abl inhibitor to be approved for sale in the market for the treatment of Bcr Abl mutation positive chronic myeloid leukemia and patients having the T315I mutation. It is a third-generation Bcr Abl inhibitor, which was granted accelerated approval in the US in 2021, which successfully turned into a full approval in 2022. Scemblix and other new-generation Bcr Abl inhibitors have been designed to specifically treat patients who have developed resistance to treatment with Imatinib. Along with this, they have also been designed to counter the T315I mutation, which is notable for helping develop resistance to tyrosine kinase inhibitors.

In 2022, the market for Bcr Abl inhibitors was valued around US$ 6 Billion, with Sprycel making up 27% of this. Developed by Bristol-Myers Squibb, Sprycel has been approved for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phases, adults with chronic, accelerated, or myeloid or lymphoid blast phase Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) who have developed resistance to or intolerance to prior therapies, such as Imatinib. In addition, Sprycel can also be used for the treatment of adults with Ph+ acute lymphoblastic leukemia (Ph+ ALL), who have developed resistance to or intolerance to prior therapy, including Imatinib. Its approval as a first-line therapy has played a crucial role in its increasing sales, which have been rising every year.

While the market is majorly dominated by certain pharmaceutical companies such as Novartis, Pfizer, Bristol-Myers Squibb and Bayer, smaller companies have been venturing into the market too with their novel Bcr Abl inhibitors, which are aimed to provide better therapeutic effects with limited adverse effects compared to these drugs having an already established market. For instance, Fusion Pharma, a Russia-based company, has been conducting clinical trials for its candidate PF-114 for the treatment of patients with resistance forms of chronic myeloid leukemia, including those having T315I mutation. While phase I/II trials for PF-114 are underway, the company has planned phase 3 trials for using the drug as a 1st, 2nd and 3rd line therapies for chronic myeloid leukemia patients bearing the T315I mutation. Often referred to as a fourth-generation inhibitors PF-114 might have the key to treating patients resistant to other Bcr Abl inhibitors.

Conclusively, the research and development activities for Bcr Abl inhibitors have been gaining speed in the recent years as more of these are getting approved in the past few years. Moreover, with the increasing focus of the pharmaceutical industry of addressing the needs of rare cancers, more companies are expected to delve in the development of novel Bcr Abl inhibitors having unique mechanisms of action. Additionally, the patent expirations of the approved drugs have allowed the entry of generic versions in the market, that have helped increase the accessibility of patients to these drugs, therefore boosting the generic drugs market as well. Several favorable parameters are currently fanning market growth as a result of which, the Bcr Abl inhibitors market is anticipated to gain more attention and investments in the coming years.

1. Introduction to BCR-ABL Inhibitors

1.1 Overview
1.2 Mechanism of Action of BCR-ABL Inhibitors
1.3 Role of BCR-ABL Inhibitor in Cancer

2. Global BCR-ABL Inhibitor Drug Market Insight

2.1 Current Market Scenario
2.2 Future Market Opportunity

3. BCR-ABL Inhibitor Drug Market Regional Analysis

3.1 US
3.2 Europe
3.3 Japan
3.4 Rest of World

4. BCR-ABL Inhibitor Drug Market by Product

4.1 First Generation BCR-ABL Inhibitor
4.2 Second Generation BCR-ABL Inhibitor
4.3 Third Generation BCR-ABL Inhibitor

5. Imatinib - 1st Generation BCR-ABL Inhibitor

5.1 Overview
5.2 Patent & Exclusivity
5.3 Pricing & Dosage Analysis
- 5.3.1 Branded
- 5.3.2 Generic
5.4 Sales Analysis

6. Dasatinib - 2nd Generation BCR-ABL Inhibitor

6.1 Overview
6.2 Patent & Exclusivity
6.3 Pricing & Dosage Analysis
- 6.3.1 Branded
- 6.3.2 Generic
6.4 Sales Analysis

7. Nilotinib - 2nd Generation BCR-ABL Inhibitor

7.1 Overview
7.2 Patent & Exclusivity
7.3 Price & Dosage Analysis
7.4 Sales Analysis

8. Bosutinib - 2nd Generation BCR-ABL Inhibitor

8.1 Overview
8.2 Patent & Exclusivity
8.3 Pricing & Dosage Analysis
8.4 Sales Analysis

9. Ponatinib - 3rd Generation BCR-ABL Inhibitor

9.1 Overview
9.2 Patent & Exclusivity
9.3 Pricing & Dosage Analysis
9.4 Sales Analysis

10. Asciminib - 3rd Generation BCR-ABL Inhibitor

10.1 Overview
10.2 Patent & Exclusivity
10.3 Pricing & Dosage Analysis
10.4 Sales Analysis

11. Olverembatinib - 3rd Generation BCR-ABL Inhibitor

11.1 Overview & Patent Analysis
11.2 Sales Analysis

12. BCR-ABL Inhibitor Market Clinical Trial Insights

12.1 By Indication
12.2 By Company
12.3 By Country
12.4 By Patient Segment
12.5 By Phase

13. Global Bcr Abl Tyrosine Kinase Inhibitors Drugs Clinical Trials By Company, Indication & Phase

13.1 Preclinical
13.2 Phase-I
13.3 Phase-I/II
13.4 Phase-II
13.5 Phase-II/III
13.6 Phase-III
13.7 Preregistration
13.8 Registered

14. Marketed Bcr Abl Tyrosine Kinase Inhibitors Drugs Clinical Insight Company & Indication

15. BCR-ABL Inhibitors Market Dynamics

15.1 Market Favorable Parameters
15.2 Market Challenges

16. Competitive Landscape

16.1 1St Biotherapeutics
16.2 Aerovate Therapeutics
16.3 Ascentage Pharma
16.4 AtlasMedx
16.5 Bayer HealthCare
16.6 BenevolentAI
16.7 CSPC Ouyi Pharmaceutical
16.8 Deciphera Pharmaceuticals
16.9 Exvastat
16.10 Fusion Pharma
16.11 Georgetown University
16.12 Guangzhou Institutes of Biomedicine and Health
16.13 Il-Yang
16.14 Inhibikase Therapeutics
16.15 Jiangsu Hansoh Pharmaceutical
16.16 Novartis
16.17 Novartis Pharmaceuticals Corporation
16.18 Pfizer
16.19 Pharm-Sintez
16.20 Shenzhen TargetRx
16.21 Sun Pharma Advanced Research Company
16.22 Takeda
16.23 Terns Pharmaceuticals
16.24 Theseus Pharmaceuticals
16.25 Vectura
16.26 Xspray Pharma
16.27 YD Global Life Science

簡介目錄圖表

List of Figures

Figure 1-1: Therapeutic Options for Management of CML
Figure 1-2: Evolution of BCR-ABL Inhibitors Development
Figure 1-3: Imatinib -- Mechanism of Action in CML
Figure 1-4: Pathways Regulated by BCR-ABL in Cancer
Figure 2-1: Global -- Estimated Leukemia Incidences & Death, 2020 & 2025
Figure 2-2: BCR-ABL Inhibitor - Drugs Sales (US$ Million), Q1'2023
Figure 2-3: BCR-ABL Inhibitor - Drugs Sales (%), Q1'2023
Figure 2-4: BCR-ABL Inhibitor - Drugs Sales (US$ Million), 2022
Figure 2-5: BCR-ABL Inhibitor - Drugs Sales (US$ Million), 2021
Figure 2-6: BCR-ABL Inhibitor - Drugs Sales (US$ Million), 2020
Figure 2-7: BCR-ABL Inhibitor - Drugs Sales (US$ Million), 2019
Figure 2-8: Global -- BCR-ABL Inhibitors Drugs Market Opportunity (US$ Billion), 2023-2029
Figure 3-1: US -- Leukemia Incidences & Death, 2020 & 2025
Figure 3-2: US vs. ROW - BCR-ABL Inhibitor Drugs Market (US$ Billion), 2022
Figure 3-3: US vs. ROW - BCR-ABL Inhibitor Drugs Market (%), 2022
Figure 3-4: US -- BCR-ABL Inhibitors Drugs Market Opportunity (US$ Billion), 2023 -- 2029
Figure 3-5: Europe -- Leukemia Incidences & Death, 2020 & 2025
Figure 3-6: Europe -- BCR-ABL Inhibitors Drugs Market Opportunity (US$ Million), 2023 - 2029
Figure 3-7: Japan -- Leukemia Incidences & Death, 2020 & 2025
Figure 3-8: Japan -- BCR-ABL Inhibitors Drugs Market Opportunity (US$ Million), 2022 -- 2028
Figure 3-9: China -- Leukemia Incidences & Death, 2020 & 2025
Figure 3-10: India -- Leukemia Incidences & Death, 2020 & 2025
Figure 3-11: China -- BCR-ABL Inhibitors Drugs Market Opportunity (US$ Million), 2023 - 2029
Figure 4-1: First Generation vs. Others -- BCR-ABL Inhibitor Drugs Market (US$ Million), Q1'2023
Figure 4-2: First Generation vs. Others -- BCR-ABL Inhibitor Drugs Market (%), Q1'2023
Figure 4-3: First Generation vs. Others -- BCR-ABL Inhibitor Drugs Market (US$ Million), 2022
Figure 4-4: First Generation vs. Others -- BCR-ABL Inhibitor Drugs Market (%), 2022
Figure 4-5: Second Generation vs. Others -- BCR-ABL Inhibitor Drugs Market (US$ Million), Q1'2023
Figure 4-6: Second Generation vs. Others -- BCR-ABL Inhibitor Drugs Market (%), Q1'2023
Figure 4-7: Second Generation BCR-ABL Inhibitor Drugs Market by Drug Type (US$ Million), Q1'2023
Figure 4-8: Second Generation BCR-ABL Inhibitor Drugs Market by Drug Type (%), Q1'2023
Figure 4-9: Second Generation vs. Others -- BCR-ABL Inhibitor Drugs Market (US$ Million), 2022
Figure 4-10: Second Generation vs. Others -- BCR-ABL Inhibitor Drugs Market (%), 2022
Figure 4-11: Second Generation BCR-ABL Inhibitor Drugs Market by Drug Type (US$ Million), 2022
Figure 4-12: Second Generation BCR-ABL Inhibitor Drugs Market by Drug Type (%), 2022
Figure 4-13: Third Generation vs. Others -- BCR-ABL Inhibitor Drugs Market (US$ Million), Q1'2023
Figure 4-14: Third Generation vs. Others -- BCR-ABL Inhibitor Drugs Market (%), Q1'2023
Figure 4-15: Third Generation vs. Others -- BCR-ABL Inhibitor Drugs Market (US$ Million), 2022
Figure 4-16: Third Generation vs. Others -- BCR-ABL Inhibitor Drugs Market (%), 2022
Figure 5-1: US -- Imatinib FDA Orphan Drug Designation by Indication
Figure 5-2: Imatinib -- Approval Year by Region
Figure 5-3: US -- Gleevec FDA Approval History by Indication
Figure 5-4: US -- Gleevec Patent Approval & Expiration Year
Figure 5-5: Imatinib -- Ist Generic Approval by Region
Figure 5-6: US -- Cost of Supply of 90 Tablets & Per Unit Cost of Gleevec 100mg (US$), April'2023
Figure 5-7: US -- Cost of Supply of 30 Tablets & Per Unit Cost of Gleevec 400mg (US$), April'2023
Figure 5-8: UK -- Cost of Supply of 60 Tablets & Per Unit Cost of Glivec 100mg (GBP/US$), April'2023
Figure 5-9: UK -- Cost of Supply of 30 Tablets & Per Unit Cost of Glivec 400mg (GBP/US$), April'2023
Figure 5-10: US -- Cost of Supply of 30 Tablets & Per Unit Cost of Imatinib 100mg (US$), April'2023
Figure 5-11: US -- Cost of Supply of 90 Tablets & Per Unit Cost of Imatinib 100mg (US$), April'2023
Figure 5-12: US -- Cost of Supply of 30 Tablets & Per Unit Cost of Imatinib 400mg (US$), April'2023
Figure 5-13: UK -- Cost of Supply of 60 Tablets & Per Unit Cost of Imatinib 100mg (GBP/US$), April'2023
Figure 5-14: UK -- Cost of Supply of 30 Tablets & Per Unit Cost of Glivec 400mg (GBP/US$), April'2023
Figure 5-15: Imatinib -- Recommended Initial Dose in Adult by Therapeutic Condition (mg/day)
Figure 5-16: Global - Gleevec/Glivec Annual Sales (US$ Million), 2019-2023
Figure 5-17: US - Gleevec/Glivec Yearly Sales (US$ Million), 2019-2023
Figure 5-18: ROW - Gleevec/Glivec Yearly Sales (US$ Million), 2019-2023
Figure 5-19: Regional - Gleevec/Glivec Quarterly Sales (US$ Million), Q1'2023
Figure 5-20: Gleevec/Glivec -- Annual Sales by Region (%), Q1'2023
Figure 5-21: Global - Gleevec/Glivec Quarterly Sales (US$ Million), 2022
Figure 5-22: Regional - Gleevec/Glivec Quarterly Sales (US$ Million), 2022
Figure 5-23: Gleevec/Glivec -- Annual Sales by Region (%), 2022
Figure 6-1: US - Sprycel Orphan Drug Designation Approval & Exclusivity for CML
Figure 6-2: US - Sprycel Orphan Drug Designation Approval & Exclusivity for Ph+ ALL
Figure 6-3: US - Sprycel Orphan Drug Designation & FDA Approval Year
Figure 6-4: Sprycel -- Approval Year by Region
Figure 6-5: US -- Sprycel Approval Year by Indication
Figure 6-6: US -- Sprycel Patent Approval & Expiration Year
Figure 6-7: Japan -- Sprycel Approval & Patent Exclusivity Year
Figure 6-8: Europe -- Branded & 1st Generic Approval Year
Figure 6-9: US -- Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 20mg (US$), April'2023
Figure 6-10: US -- Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 50mg & 70mg (US$), April'2023
Figure 6-11: US -- Cost of Supply of 30 Tablets & Per Unit Cost of Sprycel 80mg, 100mg & 140mg (US$), April'2023
Figure 6-12: UK -- Cost of Supply of 60 Tablets & Per Unit Cost of Sprycel 20mg (GBP/US$), April'2023
Figure 6-13: UK -- Cost of Supply of 60/30 Tablets & Per Unit Cost of Sprycel 50mg, 80mg, 100mg & 140mg (GBP/US$), April'2023
Figure 6-14: UK -- Cost of Supply of 60 Tablets & Per Unit Cost of Dasatinib 20mg (GBP/US$), April'2023
Figure 6-15: UK -- Cost of Supply of 30 Tablets & Per Unit Cost of Dasatinib 50mg, 80mg, 100mg & 140mg (GBP/US$), April'2023
Figure 6-16: Dasatinib -- Initial Recommended Dose by Indication for Adults (mg/day)
Figure 6-17: Dasatinib -- Initial Recommended Dose by Indication for Pediatric Patients by Weight (mg/day)
Figure 6-18: Global - Sprycel Annual Sales (US$ Million), 2019-2023
Figure 6-19: Regional -- Sprycel Annual Sales (US$ Million), Q1'2023
Figure 6-20: Regional -- Sprycel Annual Sales (%), Q1'2023
Figure 6-21: Regional -- Sprycel Annual Sales (US$ Million), 2022
Figure 6-22: Regional -- Sprycel Annual Sales (%), 2022
Figure 6-23: Global - Sprycel Quarterly Sales (US$ Million), 2022
Figure 6-24: US - Sprycel Quarterly Sales (US$ Million), 2022
Figure 6-25: ROW - Sprycel Quarterly Sales (US$ Million), 2022
Figure 6-26: US - Sprycel Annual Sales (US$ Million), 2019-2023
Figure 6-27: ROW - Sprycel Annual Sales (US$ Million), 2019-2023
Figure 7-1: US - Tasigna Orphan Drug Designation Approval & Exclusivity for CML
Figure 7-2: Tasigna -- Approval Year by Region
Figure 7-3: US - Tasigna Orphan Drug Designation & Approval Year
Figure 7-4: Europe - Tasigna Orphan Drug Designation & Approval Year
Figure 7-5: US -- Tasigna Approval History by Indication
Figure 7-6: US -- Tasigna Patent Approval & Expiration Year
Figure 7-7: Canada -- Tasigna Patent Approval & Expiration Year
Figure 7-8: US -- Tasigna FDA Approval & Patent Exclusivity Year
Figure 7-9: Europe -- Tasigna EMA Approval & Patent Exclusivity Year
Figure 7-10: US -- Cost of Supply of 120 Capsules & Per Unit Cost of Tasigna 50mg (US$), April'2023
Figure 7-11: US -- Cost of Supply of 28 Capsules & Per Unit Cost of Tasigna 150mg & 200mg (US$), April'2023
Figure 7-12: US -- Cost of Supply of 112 Capsules & Per Unit Cost of Tasigna 1500mg & 200mg (US$), April'2023
Figure 7-13: UK -- Cost of Supply of 120 Capsules & Per Unit Cost of Tasigna 50mg (GBP/US$), April'2023
Figure 7-14: UK -- Cost of Supply of 112 Capsules & Per Unit Cost of Tasigna 150mg & 200mg (GBP/US$), April'2023
Figure 7-15: Nilotinib -- Initial Recommended Dose by Indication (mg/day)
Figure 7-16: Nilotinib -- Minimum & Maximum Recommended Dose in Pediatric CML (mg/day)
Figure 7-17: Global - Tasigna Annual Sales (US$ Million), 2019-2023
Figure 7-18: Tasigna -- Annual Sales by Region (US$ Million), 2022
Figure 7-19: Tasigna -- Annual Sales by Region (%), 2022
Figure 7-20: Global - Tasigna Quarterly Sales (US$ Million), 2022
Figure 7-21: US - Tasigna Quarterly Sales (US$ Million), 2022
Figure 7-22: ROW - Tasigna Quarterly Sales (US$ Million), 2022
Figure 7-23: US - Tasigna Annual Sales (US$ Million), 2019-2023
Figure 7-24: ROW - Tasigna Annual Sales (US$ Million), 2019-2023
Figure 8-1: US - Bosulif Orphan Drug Designation Approval & Exclusivity for CML
Figure 8-2: Bosulif -- Approval Year by Region
Figure 8-3: US - Bosulif Orphan Drug Designation & Approval Year
Figure 8-4: US - Bosulif Approval by Indication
Figure 8-5: US -- Bosulif Patent Approval & Expiration Years
Figure 8-6: Europe -- Bosulif EMA Approval & Patent Exclusivity Year
Figure 8-7: US -- Cost of Supply of 120 Tablets & Per Unit Cost of Bosulif 100mg (US$), April'2023
Figure 8-8: US -- Cost of Supply of 120 Tablets & Per Unit Cost of Bosulif 400mg & 500mg (US$), April'2023
Figure 8-9: UK -- Cost of Supply of 28 Tablets & Per Unit Cost of Basulif 100mg (GBP/US$), April'2023
Figure 8-10: UK -- Cost of Supply of 28 Tablets & Per Unit Cost of Bosulif 400mg & 500mg (GBP/US$), April'2023
Figure 8-11: Bosulif-- Initial Recommended Dose by Indication for Adults (mg/day)
Figure 8-12: Bosulif-- Minimum & Maximum Recommended Dose (mg/day)
Figure 8-13: Global - Bosulif Annual Sales (US$ Million), 2019-2023
Figure 8-14: US - Bosulif Annual Sales (US$ Million), 2019-2023
Figure 8-15: Europe - Bosulif Annual Sales (US$ Million), 2019-2023
Figure 8-16: Regional -- Bosulif Quarterly Sales (US$ Million), Q1'2023
Figure 8-17: Regional -- Bosulif Quarterly Sales (%), Q1'2023
Figure 8-18: Bosulif -- Annual Sales by Region (US$ Million), 2022
Figure 8-19: Bosulif -- Annual Sales by Region (%), 2022
Figure 8-20: Global - Bosulif Quarterly Sales (US$ Million), 2022
Figure 8-21: US - Bosulif Quarterly Sales (US$ Million), 2022
Figure 8-22: Europe - Bosulif Quarterly Sales (US$ Million), 2022
Figure 8-23: ROW - Bosulif Quarterly Sales (US$ Million), 2022
Figure 9-1: Iclusig - Orphan Drug Designation by Region
Figure 9-2: US - Iclusig Orphan Drug Designation & Approval Year
Figure 9-3: Europe - Iclusig Orphan Drug Designation & Approval Year
Figure 9-4: Iclusig -- Approval Year by Region
Figure 9-5: US -- Iclusig Approval by Indication
Figure 9-6: US -- Iclusig Patent Approval & Expiration Year
Figure 9-7: Europe -- Iclusig EMA Approval & Patent Exclusivity Year
Figure 9-8: Japan -- Iclusig Approval & Patent Exclusivity Year
Figure 9-9: US -- Cost of Supply of 30 Tablets & Per Unit Cost of Iclusig Oral Tablet (US$), April'2023
Figure 9-10: UK -- Cost of Supply of 30 Tablets & Per Unit Cost of Iclusig 15mg (GBP/US$), April'2023
Figure 9-11: UK -- Cost of Supply of 30 Tablets & Per Unit Cost of Iclusig 30mg & 45mg (GBP/US$), April'2023
Figure 9-12: Ponatinib -- Initial & Dose Reductions for CP-CML (mg/day)
Figure 9-13: Ponatinib -- Initial & Dose Reductions for Resistant CML & Ph+ ALL (mg/day)
Figure 9-14: Global - Iclusig Annual Sales (US$ Million), 2019-2023
Figure 9-15: Global - Iclusig Quarterly Sales (US$ Million), 2022
Figure 10-1: US - Scemblix Orphan Drug Designation & Approval Year
Figure 10-2: Scemblix -- Approval Year by Region
Figure 10-3: US -- Scemblix Patent Issue & Expiration Year
Figure 10-4: US -- Scemblix FDA Approval & Patent Exclusivity Year
Figure 10-5: US -- Cost of Supply of 60 Tablets & Per Unit Cost of Scemblix Oral Tablet (US$), April'2023
Figure 10-6: UK -- Cost of Supply of 60 Tablets & Per Unit Cost of Scemblix Oral Tablet (US$), April'2023
Figure 10-7: Scemblix -- Initial & Dose Reductions for Ph+ CML-CP, Previously Treated with Two or More TKIs (mg/day)
Figure 10-8: Scemblix -- Initial & Dose Reductions for Ph+ CML-CP with the T315I Mutation (mg/day)
Figure 10-9: Global - Scemblix Quarterly Sales (US$ Million), 2022-2023
Figure 10-10: Global - Scemblix Quarterly Sales (US$ Million), 2022
Figure 10-11: US - Scemblix Quarterly Sales (US$ Million), 2022
Figure 10-12: ROW - Scemblix Quarterly Sales (US$ Million), 2022
Figure 10-13: Scemblix -- Annual Sales by Region (%), 2022
Figure 11-1: China -- Olverembatinib Priority Review, Breakthrough Therapy Designation & NMPA Approval Year
Figure 11-2: Olverembatinib -- Orphan Designation by Region
Figure 11-3: Global - Olverembatinib Half-Yearly Sales (US$ Million), 2022
Figure 12-1: Global -- Bcr Abl Inhibitor Drugs in Clinical Trials by Indication, 2023
Figure 12-2: Global -- Bcr Abl Inhibitor Drugs in Clinical Trials by Company, 2023
Figure 12-3: Global -- Bcr Abl Inhibitor Drugs in Clinical Trials by Country, 2023
Figure 12-4: Global -- Bcr Abl Inhibitor Drugs in Clinical Trials by Patient Segment, 2023
Figure 12-5: Global -- Bcr Abl Inhibitor Drugs in Clinical Trials by Phase, 2023
Figure 15-1: BCR-ABL Inhibitor Market Drivers
Figure 15-2: BCR-ABL Inhibitor Market Challenges